CancerDrs

Breast Cancer clinical trials in Tennessee

52 actively recruiting breast cancer trials at 12 sites across Tennessee.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full breast cancer transparency page →

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Tennessee:
  • Baptist Memorial Hospital and Cancer Center-Collierville — Collierville, Tennessee
  • The West Clinic - Wolf River — Germantown, Tennessee
  • University of Tennessee - Knoxville — Knoxville, Tennessee
  • Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Tennessee:
  • Baptist Memorial Hospital and Cancer Center-Collierville — Collierville, Tennessee
  • The West Clinic - Wolf River — Germantown, Tennessee
  • Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 nega…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06058377
Sites in Tennessee:
  • Baptist Memorial Hospital and Cancer Center-Collierville — Collierville, Tennessee
  • Covenant Health Cancer Centers — Knoxville, Tennessee
  • Covenant Health Cancer Centers - West — Knoxville, Tennessee
  • Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
  • Covenant Health Oncology Group - Oak Ridge — Oak Ridge, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer ret…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07391774
Sites in Tennessee:
  • Baptist Memorial Hospital and Cancer Center-Collierville — Collierville, Tennessee
  • Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…

Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in Tennessee:
  • Ballad Health Cancer Care - Kingsport — Kingsport, Tennessee
  • Center for Biomedical Research, LLC — Knoxville, Tennessee
  • University of Tennessee — Knoxville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed def…

Sponsor: AstraZeneca
NCT ID: NCT05774951
Sites in Tennessee:
  • Research Site — Chattanooga, Tennessee
  • Research Site — Knoxville, Tennessee
  • Research Site — Nashville, Tennessee
  • Research Site — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positi…

Sponsor: Pfizer
NCT ID: NCT07062965
Sites in Tennessee:
  • The West Clinic, PLLC dba West Cancer Center — Germantown, Tennessee
  • SCRI Oncology Partners — Nashville, Tennessee
  • Henry-Joyce Cancer Clinic — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 60 years) tolerate side effects and stay on treatment longer, to der…

Sponsor: American Society of Clinical Oncology
NCT ID: NCT06377852
Sites in Tennessee:
  • Baptist Memorial Healthcare — Memphis, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blinded, which means neither the participant…

Sponsor: BioNTech SE
NCT ID: NCT07173751
Sites in Tennessee:
  • The West Clinic, P.C. dba West Cancer Center — Germantown, Tennessee
  • Tennessee Oncology — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…

Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in Tennessee:
  • Research Site — Chattanooga, Tennessee
  • Research Site — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in th…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06966700
Sites in Tennessee:
  • Tennessee Cancer Specialists ( Site 7001) — Knoxville, Tennessee
  • SCRI Oncology Partners ( Site 7005) — Nashville, Tennessee
  • Nashville General Hospital ( Site 0017) — Nashville, Tennessee
  • Vanderbilt-Ingram Cancer Center ( Site 0038) — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…

Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in Tennessee:
  • West Cancer Center — Germantown, Tennessee
  • Vanderbilt University Medical Center — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in Tennessee:
  • Clinical Trial Site — Bartlett, Tennessee
  • Clinical Trial Site — Knoxville, Tennessee
  • Clinical Trial Site — Mount Juliet, Tennessee
  • Clinical Trial Site — Nashville, Tennessee
  • Clinical Trial Site — Tennessee City, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+,…

Sponsor: AstraZeneca
NCT ID: NCT06380751
Sites in Tennessee:
  • Research Site — Chattanooga, Tennessee
  • Research Site — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…

Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Sites in Tennessee:
  • Tennessee Cancer Specialists — Knoxville, Tennessee
  • Tennessee Oncology, PLLC — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…

Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Sites in Tennessee:
  • Tennessee Cancer Specialists — Knoxville, Tennessee
  • SCRI Oncology Partners — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metasta…

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06435429
Sites in Tennessee:
  • Sarah Cannon Research Institute — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (H…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07060807
Sites in Tennessee:
  • SCRI Oncology Partners ( Site 7000) — Nashville, Tennessee
  • Tennessee Oncology ( Site 0068) — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

The purpose of this study is to assess the efficacy and safety of RO7771950 in combination with trastuzumab and capecitabine, compared to tucatinib in combination with trastuzumab and capecitabine.

Sponsor: Hoffmann-La Roche
NCT ID: NCT07413939
Sites in Tennessee:
  • The West Clinic, PC dba West Cancer Center — Germantown, Tennessee
  • Sarah Cannon Research Institute — Nashville, Tennessee
  • Tennessee Oncology Elliston Place Plaza — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Tennessee:
  • Baptist Memorial Hospital and Cancer Center-Collierville — Collierville, Tennessee
  • Regional Cancer Center at Johnson City Medical Center — Johnson City, Tennessee
  • Ballad Health Cancer Care - Kingsport — Kingsport, Tennessee
  • Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
  • Vanderbilt Breast Center at One Hundred Oaks — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

ATEMPT 2.0: Adjuvant T-DM1 vs TH

This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of …

Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04893109
Sites in Tennessee:
  • Greco-Hainsworth Centers for Research/Tennessee Oncology — Nashville, Tennessee
  • SCRI Oncology Partners — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer. Some patients will take both imlunestrant…

Sponsor: Eli Lilly and Company
NCT ID: NCT07287098
Sites in Tennessee:
  • Tennessee Oncology — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…

Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in Tennessee:
  • SCRI - TriStar Medical Group Children's Specialists — Nashville, Tennessee
  • SCRI Oncology Partners — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. Partic…

Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT06075953
Sites in Tennessee:
  • Vanderbilt University Medical Center — Nashville, Tennessee
View on ClinicalTrials.gov →

Showing 25 of 52 trials with sites in Tennessee. See all breast cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-12